Juno And Celltrion Partner For Australian Biosimilars Push
Australia’s Juno Pharmaceuticals has struck a deal with Korea’s Celltrion to partner on marketing biosimilar trastuzumab and rituximab.
You may also be interested in...
Celltrion Healthcare’s Truxima has become the second rituximab biosimilar to be listed on Australia’s Pharmaceutical Benefits Schedule. But unlike Sandoz’ Riximyo version, Truxima is only eligible for oncology indications under a chemotherapy funding scheme.
Tender deadline for Roche acquisition of Spark pushed back to 30 October; 21.4% of Spark shares tendered so far. Vertex further diversifies with fourth deal of 2019 – an RNA-targeted collaboration with Ribometrix.
The JV to be called JAGUAHR Therapeutics will focus on the AhR pathway. Simcere acquires Chinese rights to JW’s gout candidate.